Neurologic complications of antitumor antibody therapies

Current Neurology and Neuroscience Reports

Volumn 8, Issue 3, 2008, Pages 259-263

  Kreisl, Teri N ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALEMTUZUMAB; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CANCER ANTIBODY; CETUXIMAB; COTARA; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; DOXORUBICIN; FLUOROURACIL; FOLINIC ACID; GEMTUZUMAB OZOGAMICIN; IBRITUMOMAB TIUXETAN; IMMUNOLOGIC AGENT; IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY I 131; OXALIPLATIN; PANITUMUMAB; PREDNISOLONE; PREDNISONE; RITUXIMAB; TOSITUMOMAB I 131; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; VINCRISTINE; WARFARIN;

ANXIETY DISORDER; ASTHENIA; BLEEDING DISORDER; BRAIN EDEMA; BRAIN HEMORRHAGE; BRAIN INFECTION; CEREBRAL BLINDNESS; CLINICAL TRIAL; COLORECTAL CANCER; CONFUSION; DRUG BINDING SITE; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG RECEPTOR BINDING; DRUG SUBSTITUTION; DRUG TOLERABILITY; GASTROINTESTINAL SYMPTOM; HEMATOLOGIC MALIGNANCY; HEMIPARESIS; HUMAN; HYPERTENSION; HYPERVOLEMIA; INCIDENCE; INSOMNIA; KIDNEY DYSFUNCTION; LEUKOENCEPHALOPATHY; MALAISE; MALIGNANT NEOPLASTIC DISEASE; MENTAL HEALTH; MONOTHERAPY; NEUROLOGIC DISEASE; NEUROLOGICAL COMPLICATION; NEUROPATHY; NEUROTOXICITY; NONHODGKIN LYMPHOMA; PERIPHERAL NEUROPATHY; PROTEINURIA; RADIATION NECROSIS; RADIOIMMUNOTHERAPY; REVIEW; SEIZURE; SENSORY NEUROPATHY; SIDE EFFECT; SKIN TOXICITY; STROKE; THROMBOEMBOLISM; TRANSIENT ISCHEMIC ATTACK; VENOUS THROMBOEMBOLISM; WOUND HEALING IMPAIRMENT; IMMUNOLOGY; NEOPLASM;

ANTIBODIES, NEOPLASM; HUMANS; NEOPLASMS; NERVOUS SYSTEM DISEASES;

EID: 49649110612     PISSN: 15284042     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11910-008-0039-5     Document Type: Review

References (31)

1. Reff ME, Carner K, Chambers KS, et al.: Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 1994, 83:435-445.
2. Demidem A, Lam T, Alas S, et al.: Chimeric anti-CD20 (IDEC-C2138) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs. Cancer Biother Radiopbarm 1997, 12:177-186.
3. Hurwitz H, Fehrenbacher L, Novotny W, et al.: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004, 350:2335-2342.
4. Emmanouilides C, Sfakiotaki G, Androulakis N, et al.: Front-line bevacizumab in combination with oxaliplatin, leucovorin and 5-fluorouracil (FOLFOX) in patients with metastatic colorectal cancer: a multicenter phase II study. BMC Cancer 2007, 7:91.
5. Kerr C: Bevacizumab and chemotherapy improves survival in NSCLC. Lancet Oncol 2005, 6:266.
6. Hurwitz HI, Fehrenbacher L, Hainsworth JD, et al.: Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer. J Clin Oncol 2005, 23:3502-3508.
7. Nguyen TD, Abrey LE: Intracranial hemorrhage in patients treated with bevacizumab and low-molecular weight heparin. Clin Adv Hematol Oncol 2007, 5:375-376; discussion 377-379.
8. Scappaticci FA, Skillings JR, Holden SN, et al.: Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J Natl Cancer Inst 2007, 99:1232-1239.
9. Hambleton J, Skillings J, Kabbinavar F, et al.: Safety of low-dose aspirin (ASA) in a pooled analysis of 3 randomized, controlled trials (RCTs) of bevacizumab (BV) with chemotherapy (CT) in patients (pts) with metastatic colorectal cancer (mCRC) [abstract]. Am Soc Clin Oncol 2005, 23:3554.
10. Vredenburgh JJ, Desjardins A, Herndon JE 2nd, et al.: Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res 2007, 13:1253-1259.
11. Vredenburgh JJ, Desjardins A, Herndon JE 2nd, et al.: Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol 2007, 25:4722-4729.
12. Avastin shows encouraging results in phase II study in patients with the most aggressive form of brain cancer [news release]. South San Francisco, CA: Genentech; November 18, 2007.
13. Tam CS, Galanos J, Seymour JF, et al.: Reversible posterior leukoencephalopathy syndrome complicating cytotoxic chemotherapy for hematologic malignancies. Am J Hematol 2004, 77: 72-76.
14. Norman JK, Parke JT, Wilson DA, McNall-Knapp RY: Reversible posterior leukoencephalopathy syndrome in children undergoing induction therapy for acute lymphoblastic leukemia. Pediatr Blood Cancer 2007, 49:198-203.
15. Allen JA, Adlakha A, Bergethon PR: Reversible posterior leukoencephalopathy syndrome after bevacizumab/FOL-FIRI regimen for metastatic colon cancer. Arch Neurol 2006, 63:1475-1478.
16. Glusker P, Recht L, Lane B: Reversible posterior leukoencephalopathy syndrome and bevacizumab [letter]. N Engl J Med 2006, 354:980-982; discussion 982.
17. Ozcan C, Wong SJ, Hari P: Reversible posterior leukoencephalopathy syndrome and bevacizumab [letter]. N Engl J Med 2006, 354:980-982; discussion 982.
18. Cobleigh MA, Langmuir VK, Sledge GW, et al.: A phase I/ II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer. Semin Oncol 2003, 30:117-124.
19. Haefner MD, Siciliano RD, Widmer LA, et al.: Reversible posterior leukoencephalopathy syndrome after treatment of diffuse large B-cell lymphoma. Onkologie 2007, 30:138-140.
20. Goldberg SL, Pecora AL, Alter RS, et al.: Unusual viral infections (progressive multifocal leukoencephalopathy and cytomegalovirus disease) after high-dose chemotherapy with autologous blood stem cell rescue and peritransplantation rituximab. Blood 2002, 99:1486-1488.
21. Freim Wahl SG, Folvik MR, Torp SH: Progressive multifocal leukoencephalopathy in a lymphoma patient with complete remission after treatment with cytostatics and rituximab: case report and review of the literature. Clin Neuropathol 2007, 26:68-73.
22. Kranick SM, Mowry EM, Rosenfeld MR: Progressive multifocal leukoencephalopathy after rituximab in a case of non-Hodgkin lymphoma. Neurology 2007, 69:704-706.
23. Pelosini M, Focosi D, Rita F, et al.: Progressive multifocal leukoencephalopathy: report of three cases in HIV-negative hematological patients and review of literature. Ann Hematol 2007 Dec 7 (Epub ahead of print).
24. Rituxan warning. FDA Consumer 2007, 41:3.
25. Marcus R, Imrie K, Belch A, et al.: CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood 2005, 105:1417-1423.
26. Bonner JA, Harari PM, Giralt J, et al.: Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006, 354:567-578.
27. Jonker DJ, O'Callaghan CJ, Karapetis CS, et al.: Cetuximab for the treatment of colorectal cancer. N Engl J Med 2007, 357:2040-2048.
28. ERBITUX (Cetuximab) package insert. ImClone Systems Incorporated, New York, NY, and Bristol-Myers Squibb Company, Princeton, NJ: May 2007.
29. Van Cutsem E, Siena S, Humblet Y, et al.: An open-label, single-arm study assessing safety and efficacy of panitumumab in patients with metastatic colorectal cancer refractory to standard chemotherapy. Ann Oncol 2008, 19:92-98.
30. Patel SJ, Shapiro WR, Laske DW, et al.: Safety and feasibility of convection-enhanced delivery of Cotara for the treatment of malignant glioma: initial experience in 51 patients. Neurosurgery 2005, 56:1243-1252; discussion 1252-1253.
31. Reardon DA, Akabani G, Coleman RE, et al.: Salvage radioimmunotherapy with murine iodine-131-labeled antitenascin monoclonal antibody 81C6 for patients with recurrent primary and metastatic malignant brain tumors: phase II study results. J Clin Oncol 2006, 24:115-122.